title: [Management of feto-maternal red cell allo-immunizations].
abstract: Feto-maternal red cell alloimmunization is defined by the presence in a pregnant woman of alloantibodies directed against blood group antigens present on the red blood cells of the fetus and inherited from the father. It arises from the immune response to a first contact to these same antigens during a prior transfusion, transplant or pregnancy. The placental transfer and the fixation of the antibodies on the fetal red cells antigenic targets lead to a haemolysis in the fetus and the newborn. The resulting haemolytic disease can show different clinical forms, from a mild anaemia with neonatal hyperbilirubinemia to a major fetal damage with stillbirth caused by hydrops fetalis. The objective of management strategies of feto-maternal alloimmunization is to detect and monitor maternal alloimmunization and to appreciate the effects on the fetus or the newborn. Since a few years, some new non-invasive techniques of surveillance are used, for instance fetal RHD genotyping on maternal plasma and evaluation of fetal anaemia through velocimetry measurement of the blood flow in the middle cerebral artery. The need for a careful postnatal surveillance has to be emphasized due to the neonatal anaemia, which can be prolonged, and to the resurgence of cases of severe neonatal icteruses recently reported by the Académie de Médecine. The policy of prevention of anti-RH1 alloimmunization should also benefit from the evolution of biological techniques by allowing an improved targeting of concerned women.
authors.affiliation: EFS Rhône-Alpes, site du groupement hospitalier Est, 28, avenue du Doyen Lépine, 69677 Bron cedex, France. pascaline.bricca@efs.sante.fr
authors.forename: P
authors.initials: P
authors.lastname: Bricca
authors.forename: E
authors.initials: E
authors.lastname: Guinchard
authors.forename: C
authors.initials: C
authors.lastname: Guitton Bliem
mesh_terms: D000653:Amniotic Fluid / Q000737:chemistry; D001783:Blood Flow Velocity; D001789:Blood Group Antigens / Q000032:analysis / Q000235:genetics / Q000276:immunology; D001787:Blood Group Incompatibility / Q000175:diagnosis / Q000196:embryology / Q000276:immunology*; D001788:Blood Grouping and Crossmatching / Q000379:methods; D001805:Blood Transfusion, Intrauterine; D004899:Erythroblastosis, Fetal / Q000209:etiology / Q000276:immunology / Q000517:prevention & control* / Q000628:therapy; D017707:Erythrocyte Transfusion; D004912:Erythrocytes / Q000276:immunology*; D005260:Female; D005312:Fetal Blood / Q000276:immunology; D005313:Fetal Death / Q000209:etiology / Q000517:prevention & control; D005315:Fetal Diseases / Q000097:blood / Q000000981:diagnostic imaging / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D005331:Fetomaternal Transfusion / Q000276:immunology*; D006801:Humans; D051556:Hyperbilirubinemia, Neonatal / Q000209:etiology / Q000276:immunology / Q000517:prevention & control*; D007231:Infant, Newborn; D007518:Isoantibodies / Q000008:administration & dosage / Q000097:blood* / Q000276:immunology / Q000627:therapeutic use; D020768:Middle Cerebral Artery / Q000000981:diagnostic imaging / Q000196:embryology; D011247:Pregnancy; D011295:Prenatal Care / Q000379:methods / Q000592:standards; D012203:Rh Isoimmunization / Q000209:etiology / Q000276:immunology / Q000517:prevention & control; D018029:Rho(D) Immune Globulin; D016216:Ultrasonography, Prenatal / Q000379:methods
chemical_list: D001789:Blood Group Antigens; D007518:Isoantibodies; C061961:RHO(D) antibody; D018029:Rho(D) Immune Globulin